CHICAGO--(BUSINESS WIRE)--OMX Ventures, a life sciences venture capital firm investing in companies that operate at the intersection of biology, big data, and engineering, announced that Swetha Murali, Ph.D. has joined the OMX team as a Senior Associate based in Boston. Working closely with the OMX Ventures partners, Swetha will be involved in all aspects of the OMX Ventures investment process from deal sourcing and diligence to investment monitoring at the board level. She will also be instrumental to the team’s activities in new company creation, especially through the application of emerging technologies that can address historically overlooked or under-appreciated areas of biology.
“Swetha joins OMX with a particularly strong background in identifying novel emerging technologies and creating valuable drug development platforms around them,” said Daniel Fero, Ph.D., Managing Director. “We are incredibly excited to add her skills and insight to the investment team at OMX. She brings a proven aptitude for translating new scientific ideas into exciting companies, and a great ability to think strategically about company scaling and product fit. Her strengths are a perfect match with our style of working as hands-on investors and company builders with our portfolio company CEOs.”
“I am delighted to join this enthusiastic and successful team of investors,” said Dr. Murali. “I share their vision that emerging technologies have tremendous potential to shape the future of biology and society. OMX has built strong relationships with both founders and investors throughout the life sciences and tech communities. I am excited to help expand these relationships and OMX’s capabilities as we continue to invest in, grow, and create companies.”
About Swetha Murali
Swetha Murali brings deep operational and scientific expertise to the OMX Ventures team. Prior to OMX, she was an Associate at Flagship Pioneering, where she co-founded three companies and supported later-stage companies. She has 10 years of scientific training in neuroscience and preclinical therapeutic development. She completed her postdoc at Boston Children’s Hospital/Harvard Medical School and Ph.D. at the University of Sydney.
About OMX Ventures (pronounced “omics”)
OMX Ventures is a U.S. venture capital investment firm focused on investing in a new era of bioengineering and its application for better tools, medicines, foods, industrial products, and more. We are centered at the intersection of biology, big data, and engineering, with focused interest in life sciences tools and technologies, therapeutics, and synthetic biology. The firm was founded in 2020 by partners who have co-invested and built successful companies together in these fields for over a decade. OMX Ventures first fund, OMX Ventures Fund I, has raised more than $150 million in committed capital, which is invested in primarily Seed and Series A investments.
Our strategy is to invest early, planting the seeds for successful company growth; to build conviction and ownership in the most promising leaders through subsequent investment; and to advise and guide portfolio companies throughout their corporate life cycle. For more information, please visit our website at http://www.omx.vc. Follow us on Twitter and LinkedIn.